Skip to main content
SpringerLink
Log in

Looking for cost-effective eye treatments

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. funded by Beijing Novartis Pharma Ltd, China

  2. funded by Novartis Farmaceutica, Mexico

  3. funded by Novartis AG, Switzerland

  4. funded by Bayer AB, Sweden

References

  1. Ying X, et al. Cost-Utility Analysis of Recommended Ranibizumab Regimen for Age-Related Macular Degeneration in China. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PSS31, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39222.

  2. Feng S, et al. Cost-Effectiveness of Ranibizumab Versus Photodynamic Therapy for the Treatment of Neovascluar Age-Related Macular Degeneration Based in China Cost Setting. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PSS30, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39185.

  3. Ruiz Miranda CI, et al. Cost-Effectiveness of Ranibizumab on Patients with Diffuse Diabetic Macular Edema Within the Public Mexican Health Care System. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PSS23, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=38951.

  4. Haig J, et al. Cost-Effectiveness of Ranibizumab Versus Aflibercept in Treatment of Treatment of Visual Impairment Due to Diabetic Macular Oedema (DMO). 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PSS34, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39196.

  5. Eriksson M, et al. Cost-Effectiveness of Aflibercept in the Treatment of Macular Oedema Secondary to Central Retinal Vein Occlusion in Sweden. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PSS26, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39138.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Looking for cost-effective eye treatments. PharmacoEcon Outcomes News 717, 25 (2014). https://doi.org/10.1007/s40274-014-1750-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1750-x

Search

Navigation